Aridis Pharmaceuticals Inc. (ARDS): Price and Financial Metrics

Aridis Pharmaceuticals Inc. (ARDS)

Today's Latest Price: $6.25 USD

0.46 (7.94%)

Updated Apr 9 12:00am

Add ARDS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ARDS Stock Summary

  • Aridis Pharmaceuticals Inc's stock had its IPO on August 14, 2018, making it an older stock than just 2.16% of US equities in our set.
  • The ratio of debt to operating expenses for Aridis Pharmaceuticals Inc is higher than it is for about just 0.34% of US stocks.
  • With a price/sales ratio of 19.38, Aridis Pharmaceuticals Inc has a higher such ratio than 94.68% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Aridis Pharmaceuticals Inc are UMRX, ALPN, PTI, XENE, and GRTS.
  • ARDS's SEC filings can be seen here. And to visit Aridis Pharmaceuticals Inc's official web site, go to
ARDS Daily Price Range
ARDS 52-Week Price Range

ARDS Stock Price Chart More Charts

ARDS Price/Volume Stats

Current price $6.25 52-week high $12.40
Prev. close $5.79 52-week low $3.80
Day low $5.83 Volume 1,100
Day high $6.25 Avg. volume 12,387
50-day MA $6.17 Dividend yield N/A
200-day MA $7.01 Market Cap 55.70M

Aridis Pharmaceuticals Inc. (ARDS) Company Bio

Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. The company was founded in 2003 and is based in San Jose, California.

ARDS Latest News Stream

Event/TimeNews Detail
Loading, please wait...

ARDS Latest Social Stream

Loading social stream, please wait...

View Full ARDS Social Stream

ARDS Price Returns

1-mo 8.51%
3-mo -11.82%
6-mo 9.65%
1-year -38.12%
3-year N/A
5-year N/A
YTD 40.45%
2019 -59.87%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching ARDS

Want to see what other sources are saying about Aridis Pharmaceuticals Inc's financials and stock price? Try the links below:

Aridis Pharmaceuticals Inc (ARDS) Stock Price | Nasdaq
Aridis Pharmaceuticals Inc (ARDS) Stock Quote, History and News - Yahoo Finance
Aridis Pharmaceuticals Inc (ARDS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7038 seconds.